|
|
|
|
Partners |
Phyllis Gardner, M.D., has spent over 25 years in academia, medicine and industry. She began her academic medical career in 1984 at Stanford University, where she has held several positions including Senior Associate Dean for Education and Student Affairs and remains today as Professor of Medicine. From 1994 to 1996, she took a leave of absence to work at ALZA Corporation, a major drug delivery company, as a Principal Scientist, Vice President of Research and as Head of ALZA Technology Institute. She has conducted extensive research in cell biology, including gene therapy, and is widely published in the fields of cell biology and pharmacology. She has received numerous national awards and honors and serves on the Board of Directors of several public and private companies, including Corium International and Revance Therapeutics, Inc. Essex Woodlands first worked with Dr. Gardner through joint directorship of Aronex Pharmaceuticals, a Fund IV portfolio company that was acquired by
Antigenics, Inc. (NASDAQ: AGEN) in 2002.
Dr. Gardner joined Essex Woodlands in 1999. Her
expertise in
pharmacology and drug delivery has been invaluable to the Partnership in
evaluating
technology in this growing segment of the pharmaceutical sector. She was
responsible for the Partnership’s introduction to
Rinat Neurosciences, a Genentech spinout
in which Essex Woodlands became the lead investor. Rinat Neurosciences
was acquired by Pfizer, Inc. in April 2006.
Dr. Gardner holds a B.S. from the University of Illinois, where she graduated Phi Beta Kappa and Phi Kappa Phi, and an M.D. from Harvard Medical School, where she graduated Alpha Omega Alpha. She trained in internal medicine at Massachusetts General Hospital, followed by a Chief Residency at Stanford University Hospital. She completed research fellowships at the College of Physicians and Surgeons at Columbia University and University College, London, U.K. |
|
|
|
|
 |
|
|
|
